Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$160.65 USD
+0.96 (0.60%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $160.63 -0.02 (-0.01%) 5:18 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$160.65 USD
+0.96 (0.60%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $160.63 -0.02 (-0.01%) 5:18 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
Fortive Plans to Buy Johnson & Johnson's Sterilization Unit
by Zacks Equity Research
Fortive (FTV) is likely to enter the medical sterilization and disinfection market with its intended purchase of Johnson & Johnson's Sterilization business.
J&J Receives Buyout Offer for Sterilization Products Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) receives a binding offer worth $2.8 billion from Fortive Corporation for its sterilization products business.
3 Biotech Stocks Up in the Past Month on Industry Turnaround
by Zacks Equity Research
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.
Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
The FDA approves Pfizer's (PFE) sNDA seeking label expansion in third indication for Xeljanz to include moderately to severely active ulcerative colitis.
AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint
by Zacks Equity Research
AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.
Novartis Gets Approval for Remicade Biosimilar in Europe
by Zacks Equity Research
Novartis' (NVS) Sandoz wins approval for a biosimilar version of Remicade in Europe, which should further strengthen its biosimilars portfolio.
Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis
by Zacks Equity Research
Eli Lilly (LLY) gets FDA approval for label expansion of its psoriasis injection Taltz to include data for psoriasis involving the genital area.
Is Fidelity Dividend ETF for Rising Rates (FDRR) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for FDRR
Should PowerShares Dividend Achievers Portfolio (PFM) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for PFM
Will China Erase Birth Limits? Stocks & ETFs to Watch
by Sanghamitra Saha
Reports of a possible end to China's four-decade-old birth restriction may boost these stocks and ETFs.
Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval
by Zacks Equity Research
Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.
Why Is Johnson & Johnson (JNJ) Down 4.1% Since its Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar
by Zacks Equity Research
Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.
Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down
by Zacks Equity Research
Geron (GERN) beats earnings but on lower sales in Q1. Operating expenses were lower year over year.
Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?
by Zacks Equity Research
Both Merck and Pfizer reported upbeat first-quarter results on May 1
VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
by Zacks Equity Research
VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.
Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y
by Zacks Equity Research
Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q1. Revenues surge year over year on increasing sales of Vibativ and collaborative revenues.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.
Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook
by Zacks Equity Research
Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. Sales of Keytruda remain strong in the quarter.
Pfizer (PFE) Stock Falls on Q1 Sales Miss, Earnings Beat
by Zacks Equity Research
Pfizer (PFE) beats expectations for earnings but misses the same for revenues in the first quarter. It retains its previously issued guidance for 2018.
Is Fidelity Dividend ETF for Rising Rates (FDRR) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FDRR
Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.
AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains
by Zacks Equity Research
AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.
Should PowerShares Dividend Achievers Portfolio (PFM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PFM